Immediate Impact
1 by Nobel laureates 50 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Bispecific antibodies: advancing precision oncology
2024 Standout
Works of Malin Carlsson being referenced
A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Malin Carlsson | 16 | 98 | 46 | 169 | 167 | 17 | 353 | |
| Andrew Fagbemi | 17 | 40 | 45 | 36 | 51 | 21 | 349 | |
| C. C. Bowley | 5 | 7 | 45 | 122 | 72 | 15 | 404 | |
| D. N. Whitmore | 28 | 40 | 20 | 90 | 24 | 15 | 403 | |
| Marianne Forslund | 2 | 98 | 27 | 200 | 41 | 15 | 376 | |
| Jessica M. Brown | 62 | 66 | 61 | 26 | 21 | 24 | 332 | |
| Magdalen Gondor | 40 | 175 | 19 | 32 | 15 | 12 | 407 | |
| Mitsuyo Tanemura | 6 | 29 | 20 | 142 | 8 | 27 | 337 | |
| Trygve Tjade | 64 | 16 | 22 | 18 | 85 | 17 | 357 | |
| Yann-Jinn Lee | 3 | 50 | 24 | 28 | 42 | 16 | 357 | |
| P. Pileri | 7 | 40 | 41 | 164 | 11 | 19 | 390 |
All Works
Loading papers...